Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2
Journal of Clinical Oncology · 2026
DOI: 10.1200/jco-25-01648 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Adriana I Apostol und 24 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, …. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Breast Neoplasms, BRCA2 Protein, BRCA1 Protein. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
PURPOSE BRCA carriers face high risks of developing both breast and ovarian/fallopian tube cancers (hereafter referred to as ovarian ). Among BRCA carriers with ovarian cancer, it is not clear whether the risk of breast cancer is sufficiently high that risk-reducing mastectomy should be offered. This study aimed to assess the risk of breast cancer BRCA carriers after a diagnosis of ovarian cancer. METHODS We included women with a pathogenic/likely pathogenic variant in BRCA1 or BRCA2 , a diagnosis of ovarian cancer, and no other cancer history and no risk-reducing bilateral mastectomy. Women were followed for incident breast cancer from the date of ovarian cancer diagnosis or the date of baseline questionnaire, whichever came last. The 5-, 10-, and 15-year cumulative risks of breast cancer were compared for women with ovarian cancer and an age-matched set of control women without ovarian cancer. RESULTS A total of 960 participants with ovarian cancer were identified (814 BRCA1 and 146 BRCA2 carriers). After a mean follow-up of 4.9 years, 41 women (4.3%) developed breast cancer, at a mean age at diagnosis of 57.5 years (range, 39-74). Actuarial cumulative breast cancer risks after ovarian cancer were 4.4%, 8.9%, and 11.5% at 5, 10, and 15 years, respectively. Only three breast cancer–related deaths occurred. Among 741 age-matched BRCA carriers without ovarian cancer, actuarial cumulative risks of breast cancer were 20.9%, 38.6%, and 47.2% at 5, 10, and 15 years, respectively. The hazard ratio for breast cancer, after an ovarian cancer diagnosis, compared with no ovarian cancer, was 0.18 ([95% CI, 0.12 to 0.27]; P < .0001). CONCLUSION After ovarian cancer, BRCA carriers have a relatively low risk of breast cancer. Risk-reducing mastectomy should not be recommended routinely, but might be considered for long-term survivors. Magnetic resonance imaging surveillance and/or mammography is a realistic alternative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.
- Women's College Research Institute, University of Toronto, Toronto, ON, Canada.
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
- Department of Tumour Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
- Research Unit NEON-S, Faculty of Medicine and Health Technology, Tampere University and TAYS Cancer Centre, Tampere, Finland.
ORCID-Profile: Adriana I Apostol, Cezary Cybulski, Raymond H Kim, Beth Y Karlan, Intan Schrader, Teresa Ramón Y Cajal, Christian F Singer, Fergus J Couch, Dana Zakalik, Kelly Metcalfe, Olufunmilayo Olopade, Nadine Tung, Robert Fruscio, William D Foulkes, Amber Aeilts, Jan Lubinski, Steven A Narod, Joanne Kotsopoulos
Zitieren
APA
Apostol, A. I., Gronwald, J., Cybulski, C., Kim, R. H., Møller, P., Karlan, B. Y., Bordeleau, L., Schrader, I., Ramón Y Cajal, T., Pal, T., Eisen, A., Singer, C. F., Couch, F. J., Zakalik, D., Metcalfe, K., Olopade, O., Tung, N., Fruscio, R., Foulkes, W. D., …, & Hereditary Breast Cancer Clinical Study Group (2026). Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01648
Vancouver
Apostol AI, Gronwald J, Cybulski C, Kim RH, Møller P, Karlan BY, et al. Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-01648
BibTeX
@article{Apostol2026,
author = {Apostol, Adriana I and Gronwald, Jacek and Cybulski, Cezary and Kim, Raymond H and Møller, Pål and Karlan, Beth Y and Bordeleau, Louise and Schrader, Intan and Ramón Y Cajal, Teresa and Pal, Tuya and Eisen, Andrea and Singer, Christian F and Couch, Fergus J and Zakalik, Dana and Metcalfe, Kelly and Olopade, Olufunmilayo and Tung, Nadine and Fruscio, Robert and Foulkes, William D and Aeilts, Amber and Sun, Ping and Lubinski, Jan and Narod, Steven A and Kotsopoulos, Joanne and Hereditary Breast Cancer Clinical Study Group, Hereditary Breast Cancer Clinical Study Group},
title = {Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-25-01648}
}
EUVIMED